QH-101

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameQH-101
Drug Alias NameQH-101QH101
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsUpdating
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesHematologic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Qinghui Liannuo Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPla General HospitalCancer Hospital Of Chinese Academy Of Medical SciencesAnhui Provincial Hospital +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursMyelodysplastic SyndromesHematologic Neoplasms +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A